Westfield Capital Management Co. LP Cuts Stock Position in Repligen Co. (NASDAQ:RGEN)

Westfield Capital Management Co. LP lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 20.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 235,310 shares of the biotechnology company’s stock after selling 58,912 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Repligen were worth $43,278,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of RGEN. YHB Investment Advisors Inc. bought a new position in shares of Repligen during the 1st quarter valued at about $26,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the last quarter. Principal Securities Inc. bought a new position in shares of Repligen during the 4th quarter valued at about $48,000. CWM LLC boosted its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 60 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Repligen by 48.4% during the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 136 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Wednesday, June 26th. Guggenheim assumed coverage on shares of Repligen in a report on Tuesday, June 18th. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. lowered their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $194.00.

Insider Transactions at Repligen

In related news, CEO Anthony Hunt bought 2,000 shares of Repligen stock in a transaction dated Friday, June 14th. The shares were acquired at an average cost of $124.08 per share, with a total value of $248,160.00. Following the completion of the transaction, the chief executive officer now owns 165,177 shares in the company, valued at approximately $20,495,162.16. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other Repligen news, CEO Anthony Hunt acquired 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $124.08 per share, with a total value of $248,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 165,177 shares in the company, valued at approximately $20,495,162.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Down 3.0 %

Repligen stock traded down $3.82 during midday trading on Friday, reaching $123.81. The stock had a trading volume of 847,033 shares, compared to its average volume of 748,439. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The firm has a market cap of $6.92 billion, a price-to-earnings ratio of 495.26, a price-to-earnings-growth ratio of 4.14 and a beta of 0.95. The company has a fifty day moving average of $139.23 and a 200 day moving average of $167.96.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s revenue was down 17.1% compared to the same quarter last year. During the same period last year, the business posted $0.64 earnings per share. On average, analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.